{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "open-label, nonrandomized, within-patient, phase 3 trials"
      },
      "Participants": {
        "score": 2,
        "evidence": "13 centers contributed 148 patients with breast cancer"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Each patient received [ 99m Tc]tilmanocept and vital blue dye (VBD)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [ 99m Tc]tilmanocept"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "13 centers contributed 148 patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "207 of 209 nodes detected by VBD were also detected by [ 99m Tc]tilmanocept for a concordance rate of 99.04 % ( p < 0.0001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No serious adverse events were attributed to [ 99m Tc]tilmanocept"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}